CERVIX

NRG-GY006: A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer.

The purpose of this study is to compile any good or bad effects of adding triapine to the usual cisplatin chemotherapy and radiation therapy, and compare those results to using cisplatin chemotherapy and radiation therapy alone.

Learn more about the NRG-GY006 trial or call the Reading Hospital Protocol Office at 484-628-8193.

ENDOMETRIUM

NRG-GY012: A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women with Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women with Recurrent or Persistent Endometrial Cancer.

The purpose of this study is to compare the safety and effects of cediranib alone, combinations of olaparib with AZD5363 (capivasertib), or durvalumab (MEDI4736) or the combination of cediranib and durvalumab (MEDI4736).

Learn more about the NRG-GY012 trial or call the Reading Hospital Protocol Office at 484-628-8193.

 

NRG-GY018: A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer.

The purpose of this study is to compare the usual treatment of paclitaxel and carboplatin to the combination of paclitaxel, carboplatin and pembrolizumab.

Learn more about the NRG-GY018 trial or call the Reading Hospital Protocol Office at 484-628-8193.

 

GOG-3039: A Phase II Study of Abemaciclib in Combination with Letrozole in Advanced, Recurrent or Metastatic Endometroid Endometrial Cancer.

The purpose of this study is to find out if the combination of the drugs abemaciclib and letrozole is better or worse than the usual approach for treating your type of cancer.

Learn more about the GOG-3039 trial or call the Reading Hospital Protocol Office at 484-628-8193.

FALLOPIAN TUBE

GOG-3035/QPT-ORE-005: A Phase 3, Double-Blind, Placebo-Controlled, Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) In Patients with Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma.

This study is being done to see how safe and effective four doses of the experimental drug, oregovomab, is when given through a vein in your arm at the same time as specific cycles of the chemotherapy regimen consisting of paclitaxel and carboplatin.

Learn more about the GOG-3035/QPT-ORE-005 trial or call the Reading Hospital Protocol Office at 484-628-8193.

OVARY

GOG-3035/QPT-ORE-005: A Phase 3, Double-Blind, Placebo-Controlled, Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) In Patients with Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma.

This study is being done to see how safe and effective four doses of the experimental drug, oregovomab, is when given through a vein in your arm at the same time as specific cycles of the chemotherapy regimen consisting of paclitaxel and carboplatin.

Learn more about the GOG-3035/QPT-ORE-005 trial or call the Reading Hospital Protocol Office at 484-628-8193.

S1714: Neuropathy Trial (Observational Study)

Eligibility: Stg I,II or III primary non-small cell lung cancer, breast cancer or ovarian/fallopian tube cancer. Scheduled to receive taxane-based chemotherapy.

To develop and validate a prediction model of peripheral neuropathy in patients receiving taxane-based chemotherapy regimens.

Learn more about the S1714 trail or call the Phoenixville Hospital Clinical Research Office at 610-983-1811.

PERITONEAL

GOG-3035/QPT-ORE-005: A Phase 3, Double-Blind, Placebo-Controlled, Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) In Patients with Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma.

This study is being done to see how safe and effective four doses of the experimental drug, oregovomab, is when given through a vein in your arm at the same time as specific cycles of the chemotherapy regimen consisting of paclitaxel and carboplatin.

Learn more about the GOG-3035/QPT-ORE-005 trial or call the Reading Hospital Protocol Office at 484-628-8193.